About this Research Topic
Genito-urinary tumors encompass a large variety of malignancies, including prostate, urothelial, renal, and testis tumors, which historicallyhave posed significant therapeutic challenges, having often limited responses to traditional treatment modalities, such as chemotherapy.
Immune checkpoint inhibitors (ICI) have revolutionized the therapeutic scenario of many solid tumors over the last decade. In the field of genito-urinary tumors, ICI garnered a pivotal role in treating renal and urothelial carcinoma showing improvement in survival outcomes. However, in other tumors, such as prostate and testis cancer, the role of ICI remains marginal. Recently, new targeted therapies , such as new generations tyrosine-kinase inhibitors (TKI) andantibody-drug conjugates (ADC), anti-FGFR drugs, are revolutionizing the treatment landscape of these tumors, and further studies of precision treatments are currently underway.
Given that immunotherapy has transformed the therapeutic landscape of urologic malignancies, and novel agents are practice-changing candidates, it is imperative to comprehend the latest developments in this field and their clinical applicability. Furthermore, there is a critical need to identify prognostic and predictive biomarkers that can assist patients’ selection and treatment tailoring, which are underexplored.
In this Research Topic, we aim to evaluate the safety and efficacy of immunotherapy and novel treatment regimens in genito-urinary tumors, explore their mechanisms of action, and investigate the pathways of resistance. We also aim to explore the potential biomarkers and drug targets for immunotherapy and novel treatments (ADC, TKI, vaccines) in genito-urinary tumors.
We welcome submissions of Original researches, Reviews/Mini-reviews, Perspectives, Systematic Reviews and meta-analyses, covering, but not limited to, the following topics:
• Novel immunotherapeutic drugs or targeted therapeutic drugs for genito-urinary tumors;
• Biomarkers with prognostic or predictive value in patients with genito-urinary tumors;
• Clinical studies focusing on novel agents and combinations in patients with genito-urinary tumors;
• Molecular mechanism involved in the progression of genito-urinary tumors and development of drug resistance;
• Novel approaches for biomarker detection using tissue, blood, or urine.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Please note the following conflict of interest disclosures: - Dr. Brigida Anna Maiorano: consulting for Bristol-Myers Squibb, AstraZeneca, Ipsen; travel and accommodations from Ipsen, Merck, Novartis, Janssen; research funding and grant from Merck. - Dr. Carlo Messina: Travel grant: merck, gk, jansen, ipsen, baier, novartis; fee as speaker: merck, gsk, ipsen astellas, msd, astrazeneca, BMS, baier, janssen
Immune checkpoint inhibitors (ICI) have revolutionized the therapeutic scenario of many solid tumors over the last decade. In the field of genito-urinary tumors, ICI garnered a pivotal role in treating renal and urothelial carcinoma showing improvement in survival outcomes. However, in other tumors, such as prostate and testis cancer, the role of ICI remains marginal. Recently, new targeted therapies , such as new generations tyrosine-kinase inhibitors (TKI) andantibody-drug conjugates (ADC), anti-FGFR drugs, are revolutionizing the treatment landscape of these tumors, and further studies of precision treatments are currently underway.
Given that immunotherapy has transformed the therapeutic landscape of urologic malignancies, and novel agents are practice-changing candidates, it is imperative to comprehend the latest developments in this field and their clinical applicability. Furthermore, there is a critical need to identify prognostic and predictive biomarkers that can assist patients’ selection and treatment tailoring, which are underexplored.
In this Research Topic, we aim to evaluate the safety and efficacy of immunotherapy and novel treatment regimens in genito-urinary tumors, explore their mechanisms of action, and investigate the pathways of resistance. We also aim to explore the potential biomarkers and drug targets for immunotherapy and novel treatments (ADC, TKI, vaccines) in genito-urinary tumors.
We welcome submissions of Original researches, Reviews/Mini-reviews, Perspectives, Systematic Reviews and meta-analyses, covering, but not limited to, the following topics:
• Novel immunotherapeutic drugs or targeted therapeutic drugs for genito-urinary tumors;
• Biomarkers with prognostic or predictive value in patients with genito-urinary tumors;
• Clinical studies focusing on novel agents and combinations in patients with genito-urinary tumors;
• Molecular mechanism involved in the progression of genito-urinary tumors and development of drug resistance;
• Novel approaches for biomarker detection using tissue, blood, or urine.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Please note the following conflict of interest disclosures: - Dr. Brigida Anna Maiorano: consulting for Bristol-Myers Squibb, AstraZeneca, Ipsen; travel and accommodations from Ipsen, Merck, Novartis, Janssen; research funding and grant from Merck. - Dr. Carlo Messina: Travel grant: merck, gk, jansen, ipsen, baier, novartis; fee as speaker: merck, gsk, ipsen astellas, msd, astrazeneca, BMS, baier, janssen
Keywords: Immunotherapy, antibody-drug conjugates, renal cancer, urothelial cancer, prostate cancer, testis cancer, biomarker, prognostic, predictive, microenvironment
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
